Close Menu

NEW YORK – Foundation Medicine said on Tuesday that the US Food and Drug Administration has approved its FoundationOne Liquid CDx test as a companion diagnostic for three new targeted cancer therapies. 

The test was approved to help identify patients who may benefit from alpelisib (Novartis' Piqray) in advanced or metastatic breast cancer, rucaparib (Clovis Oncology's Rubraca) in advanced ovarian cancer, and alectinib (Genentech's Alecensa) in a certain kind of metastatic non-small cell lung cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.